



The following is based on the Canadian Agency for Drugs and Technologies in Health (CADTH) report, *Pharmacologic-based Strategies for Smoking Cessation: Clinical and Cost-Effectiveness Analyses* and adapted for health care providers in British Columbia (BC). Visit <http://www.cadth.ca/smokingcessationBC> for more information on the CADTH report.

Smoking is one of the major risk factors for cancer, respiratory disease, and cardiovascular disease. Smoking tobacco is a risk factor that can be changed — by quitting permanently. Unfortunately, quitting smoking is much easier said than done.

While BC has the lowest smoking rate in Canada at 14.9%, there are approximately 555,000 British Columbians who smoke. An estimated 70% of smokers in BC want to quit. However, published data suggest that, in the long term, many will fail in their attempts to quit smoking without the help of **smoking cessation aids**. Given the high number of preventable deaths and evidence indicating that more than 30% of Canadian hospital beds are occupied by adults who are there as a consequence of their smoking habits, there is a need to consider **smoking cessation strategies**.

Because smoking is an important risk factor for a variety of serious health conditions, successfully **quitting can help to prevent illness and death**. And, fortunately, many smokers want to quit. How can we best help them to quit? Which of the smoking cessation aids works best? Which of these options offers the best value to Canadians and our health care system?

To address these questions, CADTH carefully reviewed the available research to help provide some answers. In particular, CADTH:

- Compared the **pharmacological agents** to determine which of these works best (**clinical effectiveness**) at six months and 12 months after attempting to quit smoking.
- Performed an **economic analysis** to determine which smoking cessation therapy was the most cost-effective for patients, drug plans, and the Canadian health care system.

Key Findings for Health Care Providers

- All pharmacotherapies examined were more effective than the placebo at six months and one year follow-up, so patient preference can drive the choice of drug therapy.
- If all pharmacotherapies are an option for your patient, consider that the use of nicotine replacement therapy (NRT) or bupropion generally doubles the odds of a smoker quitting successfully, and the use of varenicline can increase the odds of quitting by between twofold and threefold, compared with not using any drug therapy.
- Bupropion or NRT are effective in helping smokers with cardiovascular disease or chronic obstructive pulmonary disease to quit smoking. Evidence on the long-term efficacy of pharmacotherapy in other specific populations, including adolescents, pregnant women, and those with other underlying diseases, remains limited.

- The combination of bupropion with NRT (or of combination of different NRT modalities) generally did not appear to impact long-term treatment success rates.
- Varenicline and bupropion are more cost-effective compared to NRT.

Smoking Cessation Drug Information

Varenicline (Champix): A nicotine receptor partial agonist with partial antagonist properties. Varenicline reduces cravings for nicotine and also reduces the pleasurable effects of using tobacco. (Its safety and efficacy has not been established for use during pregnancy or lactation, or for pediatric use. Use cautiously in elderly patients and in patients with significant renal impairment. Varenicline is indicated for use in conjunction with supportive counselling.)

- 0.5 mg orally, once daily (days one to three)
- 0.5 mg orally, twice daily (days four to seven)
- 1.0 mg orally, twice daily (day eight to the end of 12 weeks of treatment).

Cost of therapy in BC: \$336

Bupropion (Zyban): An atypical antidepressant that inhibits the reuptake of norepinephrine and dopamine. (Caution should be exercised when prescribing bupropion in pregnant women, elderly patients, patients with a history of seizures, patients with hepatic and renal impairment, and those with eating disorders; it is also not indicated for anyone younger than 18 years of age.)

- 150 mg orally, once daily (days one to three)
- 150 mg orally, twice daily (until the end of 12 weeks of therapy).

Cost of therapy in BC: \$209

NRT: Replaces nicotine previously derived from the use of tobacco products, administered in various forms. Maintains stimulation of nicotine receptors to minimize or eliminate craving and withdrawal symptoms. Brand name products are available in multiple forms: gum (Nicorette and Thrive), patch (Habitrol, Nicoderm, and Nicotrol), inhaler (Nicorette Inhaler), and lozenge (Nicorette and Thrive). (Caution should be exercised in prescribing NRT products to pregnant women or to patients with certain medical conditions.)

Cost of therapy in BC:

- patch is \$273
- gum, between \$122 and 289
- inhaler, between \$642 AND \$1255
- lozenge, between \$115 and \$337

NOTE: All costs are for a 12 week supply and include mark-up and dispensing fees for BC in 2011.

Also consider the financial cost of **remaining a smoker**. For example, if your patient smokes a \$10 pack of cigarettes a day, they will spend \$840 during a 12-week period.

DISCLAIMER: The information in this summary is intended to help health care decision-makers, patients, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this summary should not be used as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of the summary to ensure that its contents are accurate, complete, and up-to-date, CADTH does not make any guarantee to that effect. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or as a result of the use (or misuse) of any information contained in or implied by the information in this summary.

CADTH takes sole responsibility for the final form and content of this summary. The statements, conclusions, and views expressed herein do not necessarily represent the view of Health Canada or any provincial or territorial government. Copyright © 2011 CADTH. This report may be reproduced for non-commercial purposes only and provided appropriate credit is given to CADTH.